journal
MENU ▼
Read by QxMD icon Read
search

Blood Advances

journal
https://www.readbyqxmd.com/read/30446486/fecal-microbiota-transplantation-with-frozen-capsules-for-a-patient-with-refractory-acute-gut-graft-versus-host-disease
#1
Satoshi Kaito, Takashi Toya, Kota Yoshifuji, Shuhei Kurosawa, Kyoko Inamoto, Kozue Takeshita, Wataru Suda, Kazuhiko Kakihana, Kenya Honda, Masahira Hattori, Kazuteru Ohashi
No abstract text is available yet for this article.
November 27, 2018: Blood Advances
https://www.readbyqxmd.com/read/30442686/prognostic-value-of-d-dimer-and-markers-of-coagulation-for-stratification-of-abdominal-aortic-aneurysm-growth
#2
Alexandra C Sundermann, Keith Saum, Kelsey A Conrad, Hannah M Russell, Todd L Edwards, Kevin Mani, Martin Björck, Anders Wanhainen, A Phillip Owens
Abdominal aortic aneurysm (AAA) is associated with high morbidity and mortality and is an established cause of unbalanced hemostasis. A number of hemostatic biomarkers have been associated with AAA; however, the utility of hemostatic biomarkers in AAA diagnosis and prognosis is unclear. The aim of the present study was to characterize the potential prognostic value of D-dimer and markers of altered hemostasis in a large cohort of patients with AAAs characterized by either fast or slow aneurysm growth (frequency matched for baseline diameter) and subaneurysmal dilations...
November 27, 2018: Blood Advances
https://www.readbyqxmd.com/read/30425073/who-should-get-long-term-anticoagulant-therapy-for-venous-thromboembolism-and-with-what
#3
REVIEW
Marc Alan Rodger, Gregoire Le Gal
After an initial 3 to 6 months of anticoagulation for venous thromboembolism (VTE), clinicians and patients face an important question: "Do we stop anticoagulants or continue them indefinitely?" The decision is easy in some scenarios (eg, stop in VTE provoked by major surgery). In most scenarios, which are faced on a day-to-day basis in routine practice, it is a challenging decision because of uncertainty in estimates in the long-term risks (principally major bleeding) and benefits (reducing recurrent VTE) and the tight trade-offs between them...
November 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/30425072/when-to-obtain-genomic-data-in-acute-myeloid-leukemia-aml-and-which-mutations-matter
#4
REVIEW
Gregory W Roloff, Elizabeth A Griffiths
Mutational profiling has fundamentally changed our approach to patients with acute myeloid leukemia (AML). Patients with AML are routinely profiled for the presence of mutations in FLT3 , NPM1 , CEBPA , and, more recently, TP53 In this chapter, we review the role of mutational profiling to help define disease biology in AML, particularly among patients with putatively intermediate-risk disease. We describe the body of evidence supporting the utility of mutational profiling when performed at the time of diagnosis (to identify prognostic and targetable mutations), at the time of complete remission (to assess minimal residual disease as a marker for relapse), and at the time of relapse (to identify therapeutic targets and eligibility for clinical trials)...
November 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/30425071/stem-cell-safe-harbor-the-hematopoietic-stem-cell-niche-in-zebrafish
#5
REVIEW
Samuel J Wattrus, Leonard I Zon
Each stem cell resides in a highly specialized anatomic location known as the niche that protects and regulates stem cell function. The importance of the niche in hematopoiesis has long been appreciated in transplantation, but without methods to observe activity in vivo, the components and mechanisms of the hematopoietic niche have remained incompletely understood. Zebrafish have emerged over the past few decades as an answer to this. Use of zebrafish to study the hematopoietic niche has enabled discovery of novel cell-cell interactions, as well as chemical and genetic regulators of hematopoietic stem cells...
November 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/30425070/activity-of-eltrombopag-in-severe-aplastic-anemia
#6
REVIEW
Phillip Scheinberg
Since the approval of horse antithymocyte globulin (ATG) decades ago, there was a long hiatus in therapies with activity in severe aplastic anemia (SAA). This scenario changed in 2014 when eltrombopag, a thrombopoietin receptor agonist, was approved for SAA after an insufficient response to initial immunosuppressive therapy (IST). The basis for this approval was the observation of single-agent activity of eltrombopag in this patient population, where 40% to 50% recovered blood counts at times involving >1 lineage...
November 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/30425069/timing-of-treatment-of-smoldering-myeloma-delay-until-progression
#7
Shaji K Kumar
No abstract text is available yet for this article.
November 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/30425068/timing-of-treatment-of-smoldering-myeloma-early-treatment
#8
María-Victoria Mateos, Verónica González-Calle
No abstract text is available yet for this article.
November 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/30425067/prevalence-of-inherited-blood-disorders-and-associations-with-malaria-and-anemia-in-malawian-children
#9
Patrick T McGann, Anne M Williams, Graham Ellis, Kathryn E McElhinney, Laurel Romano, Julia Woodall, Thad A Howard, Gerald Tegha, Robert Krysiak, R Murray Lark, E Louise Ander, Carine Mapango, Kenneth I Ataga, Satish Gopal, Nigel S Key, Russell E Ware, Parminder S Suchdev
In sub-Saharan Africa, inherited causes of anemia are common, but data are limited regarding the geographical prevalence and coinheritance of these conditions and their overall contributions to childhood anemia. To address these questions in Malawi, we performed a secondary analysis of the 2015-2016 Malawi Micronutrient Survey, a nationally and regionally representative survey that estimated the prevalence of micronutrient deficiencies and evaluated both inherited and noninherited determinants of anemia. Children age 6 to 59 months were sampled from 105 clusters within the 2015-2016 Malawi Demographic Health Survey...
November 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/30425066/venous-thromboembolism-in-chronic-lymphocytic-leukemia-a-danish-nationwide-cohort-study
#10
Inger Lise Gade, Signe Juul Riddersholm, Ilse Christiansen, Annika Rewes, Mikael Frederiksen, Lisbeth Enggaard, Christian Bjørn Poulsen, Olav Jonas Bergmann, Dorte Balle Gillström, Robert Schou Pedersen, Linda Nielsen, Helle Højmark Eriksen, Christian Torp-Pedersen, Søren Risom Kristensen, Marianne Tang Severinsen
Venous thromboembolism (VTE) is associated with inferior survival in cancer patients. The risk of VTE and its effect on survival in chronic lymphocytic leukemia (CLL) patients remains unclear. The present study investigated the impact of patient-related factors, CLL prognostic markers, and CLL treatment on the risk of VTE and assessed overall survival relative to VTE. All patients in the Danish National CLL Registry (2008-2015) were followed from the date of CLL diagnosis to death, VTE, emigration, or administrative censoring...
November 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/30425065/silencing-of-hdac6-as-a-therapeutic-target-in-chronic-lymphocytic-leukemia
#11
Kamira Maharaj, John J Powers, Alex Achille, Susan Deng, Renee Fonseca, Mibel Pabon-Saldana, Steven N Quayle, Simon S Jones, Alejandro Villagra, Eduardo M Sotomayor, Eva Sahakian, Javier Pinilla-Ibarz
Although the treatment paradigm for chronic lymphocytic leukemia (CLL) is rapidly changing, the disease remains incurable, except with allogeneic bone marrow transplantation, and resistance, relapsed disease, and partial responses persist as significant challenges. Recent studies have uncovered roles for epigenetic modification in the regulation of mechanisms contributing to malignant progression of CLL B cells. However, the extent to which epigenetic modifiers can be targeted for therapeutic benefit in CLL patients remains poorly explored...
November 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/30413435/high-resolution-mapping-of-the-polyclonal-immune-response-to-the-human-platelet-alloantigen-hpa-1a-pl-a1
#12
Huiying Zhi, Maria Therese Ahlen, Aye Myat Myat Thinn, Hartmut Weiler, Brian R Curtis, Bjørn Skogen, Jieqing Zhu, Peter J Newman
Antibodies to platelet-specific antigens are responsible for 2 clinically important bleeding disorders: posttransfusion purpura and fetal/neonatal alloimmune thrombocytopenia (FNAIT). The human platelet-specific alloantigen 1a/1b (HPA-1a/1b; also known as PlA1/A2 ) alloantigen system of human platelet membrane glycoprotein (GP) IIIa is controlled by a Leu33Pro polymorphism and is responsible for ∼80% of the cases of FNAIT. Local residues surrounding polymorphic residue 33 are suspected to have a profound effect on alloantibody binding and subsequent downstream effector events...
November 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/30413434/antibody-mediated-immune-suppression-by-antigen-modulation-is-antigen-specific
#13
Cheryl L Maier, Amanda Mener, Seema R Patel, Ryan P Jajosky, Ashley L Bennett, Connie M Arthur, Jeanne E Hendrickson, Sean R Stowell
Alloantibodies developing after exposure to red blood cell (RBC) alloantigens can complicate pregnancy and transfusion therapy. The only method currently available to actively inhibit RBC alloantibody formation is administration of antigen-specific antibodies, a phenomenon termed antibody-mediated immune suppression (AMIS). A well-known example of AMIS is RhD immune globulin prophylaxis to prevent anti-D formation in RhD- individuals. However, whether AMIS is specific or impacts alloimmunization to other antigens on the same RBC remains unclear...
November 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/30413433/the-endogenous-antimicrobial-cathelicidin-ll37-induces-platelet-activation-and-augments-thrombus-formation
#14
Maryam F Salamah, Divyashree Ravishankar, Xenia Kodji, Leonardo A Moraes, Harry F Williams, Thomas M Vallance, Dina A Albadawi, Rajendran Vaiyapuri, Kim Watson, Jonathan M Gibbins, Susan D Brain, Mauro Perretti, Sakthivel Vaiyapuri
Platelet-associated complications including thrombosis, thrombocytopenia, and hemorrhage are commonly observed during various inflammatory diseases such as sepsis, inflammatory bowel disease, and psoriasis. Despite the reported evidence on numerous mechanisms/molecules that may contribute to the dysfunction of platelets, the primary mechanisms that underpin platelet-associated complications during inflammatory diseases are not fully established. Here, we report the discovery of formyl peptide receptor 2, FPR2/ALX, in platelets and its primary role in the development of platelet-associated complications via ligation with its ligand, LL37...
November 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/30413432/mayo-alliance-prognostic-system-for-mastocytosis-clinical-and-hybrid-clinical-molecular-models
#15
Animesh Pardanani, Sahrish Shah, Francesco Mannelli, Yoseph C Elala, Paola Guglielmelli, Terra L Lasho, Mrinal M Patnaik, Naseema Gangat, Rhett P Ketterling, Kaaren K Reichard, Curtis A Hanson, Alessandro M Vannucchi, Ayalew Tefferi
Systemic mastocytosis (SM) is a clinically heterogeneous disease with prognosis chiefly assigned based on World Health Organization (WHO) morphologic subclassification. We assessed the feasibility of developing contemporary risk models for SM based on clinical and integrated clinical-genetics information. Diagnosis of SM was per WHO criteria, and karyotype and next-generation sequencing data were available in a subset of the total 580 patients (median age, 55 years; range, 18-88 years) seen at the Mayo Clinic between 1968 and 2015...
November 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/30404775/a-novel-fas-mutation-with-variable-expressivity-in-a-family-with-unicentric-and-idiopathic-multicentric-castleman-disease
#16
Turner S Baker, Kristyne J Gambino, Lawrence Schriefer, Jung-Yeon Lim, Karyn Meltz Steinberg, David C Fajgenbaum, Alejandro Martín García-Sancho, Minji Byun
No abstract text is available yet for this article.
November 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/30401752/snare-dependent-membrane-fusion-initiates-%C3%AE-granule-matrix-decondensation-in-mouse-platelets
#17
Irina D Pokrovskaya, Smita Joshi, Michael Tobin, Rohan Desai, Maria A Aronova, Jeffrey A Kamykowski, Guofeng Zhang, Sidney W Whiteheart, Richard D Leapman, Brian Storrie
Platelet α-granule cargo release is fundamental to both hemostasis and thrombosis. Granule matrix hydration is a key regulated step in this process, yet its mechanism is poorly understood. In endothelial cells, there is evidence for 2 modes of cargo release: a jack-in-the-box mechanism of hydration-dependent protein phase transitions and an actin-driven granule constriction/extrusion mechanism. The third alternative considered is a prefusion, channel-mediated granule swelling, analogous to the membrane "ballooning" seen in procoagulant platelets...
November 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/30401751/insights-into-the-genomic-landscape-of-myd88-wild-type-waldenstr%C3%A3-m-macroglobulinemia
#18
Zachary R Hunter, Lian Xu, Nickolas Tsakmaklis, Maria G Demos, Amanda Kofides, Cristina Jimenez, Gloria G Chan, Jiaji Chen, Xia Liu, Manit Munshi, Joshua Gustine, Kirsten Meid, Christopher J Patterson, Guang Yang, Toni Dubeau, Mehmet K Samur, Jorge J Castillo, Kenneth C Anderson, Nikhil C Munshi, Steven P Treon
Activating MYD88 mutations are present in 95% of Waldenström macroglobulinemia (WM) patients, and trigger NF-κB through BTK and IRAK. The BTK inhibitor ibrutinib is active in MYD88- mutated (MYD88 MUT ) WM patients, but shows lower activity in MYD88 wild-type ( MYD88 WT ) disease. MYD88 WT patients also show shorter overall survival, and increased risk of disease transformation in some series. The genomic basis for these findings remains to be clarified. We performed whole exome and transcriptome sequencing of sorted tumor samples from 18 MYD88 WT patients and compared findings with WM patients with MYD88 MUT disease...
November 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/30396912/myeloablative-vs-reduced-intensity-conditioning-allogeneic-hematopoietic-cell-transplantation-for-chronic-myeloid-leukemia
#19
Saurabh Chhabra, Kwang Woo Ahn, Zhen-Huan Hu, Sandeep Jain, Amer Assal, Jan Cerny, Edward A Copelan, Andrew Daly, Zachariah DeFilipp, Shahinaz M Gadalla, Robert Peter Gale, Siddhartha Ganguly, Betty K Hamilton, Gerhard Carl Hildebrandt, Jack W Hsu, Yoshihiro Inamoto, Abraham S Kanate, H Jean Khoury, Hillard M Lazarus, Mark R Litzow, Sunita Nathan, Richard F Olsson, Attaphol Pawarode, Olle Ringden, Jacob M Rowe, Ayman Saad, Bipin N Savani, Harry C Schouten, Sachiko Seo, Nirav N Shah, Melhem Solh, Robert K Stuart, Celalettin Ustun, Ann E Woolfrey, Jean A Yared, Edwin P Alyea, Matt E Kalaycio, Uday Popat, Ronald M Sobecks, Wael Saber
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment of chronic myeloid leukemia (CML). Optimal conditioning intensity for allo-HCT for CML in the era of tyrosine kinase inhibitors (TKIs) is unknown. Using the Center for International Blood and Marrow Transplant Research database, we sought to determine whether reduced-intensity/nonmyeloablative conditioning (RIC) allo-HCT and myeloablative conditioning (MAC) result in similar outcomes in CML patients. We evaluated 1395 CML allo-HCT recipients between the ages of 18 and 60 years...
November 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/30396911/persistence-of-endothelial-thrombomodulin-in-a-patient-with-infectious-purpura-fulminans-treated-with-protein-c-concentrate
#20
Pavan K Bendapudi, Alissa Robbins, Nicole LeBoeuf, Olga Pozdnyakova, Ami Bhatt, Fujiko Duke, Ryan Sells, John McQuiston, Ben Humrighouse, Betty Rouaisnel, Meaghan Colling, Kathryn E Stephenson, Arturo Saavedra, Julie-Aurore Losman
No abstract text is available yet for this article.
November 13, 2018: Blood Advances
journal
journal
54100
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"